Breaking news: The latest ESC heart failure guidelines 2023 now recommends the implementation of STRONG-HF regimen in their recent update. This includes the rapid uptitration of guideline-directed medical therapy, coupled with frequent monitoring of NT-proBNP levels, categorised as Class I B, which marks a significant stride forward in improving patient care standards.
Learn from the Master Pack to gain more insights on STRONG-HF now!
Master Pack Details
STRONG-HF primary outcomes infographicAPSC APAC HF Consensus (Gap report to follow)Prof. Mebazaa’s HF plenary at APSCExclusive interviews with Prof Mebazaa and APAC KOLsThe latest insights in HF treatment monitoring
Submit the form and access the Master Pack.
The Master Pack features unlimited and free access to the latest STRONG-HF content, exclusively with Prof Mebazaa sharing his experiences and insights to help you master the latest concepts, processes, and tools in heart failure (HF) management.
It also features the Asian Pacific Society of Cardiology (APSC) HF Consensus and Gap Report for a first look at the unmet needs and recommendations for Asia Pacific.
Learn more about – Strong-HF Study Benefits
Embrace this opportunity and register now!
Despite advancements in cardiac care, the readmission rates for HF have not improved since the 1980s
High readmission and all-cause death
One year Asian HF readmission and all-cause death rate1:
High mortality rate
One year crude Asian all-cause mortality rate2:
STRONG-HF: the evidence-based, post-acute heart failure treatment strategy you have been waiting for
The STRONG-HF biomarker-led therapeutic strategy offers guidance on rapid induction and optimization of GDMT during the vulnerable period before and after discharge; thereby supporting HCPs in providing optimal, life-saving treatment when it is needed the most.
STRONG-HF study design
STRONG-HF results show that in the high intensity care group: 34% relative and 8.1 % absolute risk reduction (ARR) in the combination of death or heart failure readmission6.
CV (cardiovascular) death
26% lower
HF readmission
44% lower
All-cause death
16% lower
HF management has finally been mapped out with proven positive outcomes
Master Pack Details
STRONG-HF primary outcomes infographicAPSC APAC HF Consensus (Gap report to follow)Prof. Mebazaa’s HF plenary at APSCExclusive interviews with Prof Mebazaa and APAC KOLsThe latest insights in HF treatment monitoring
